EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Outcome of COVID-19 and tolerance of Remdesivir in patients with renal failure: a single center experience from Pakistan

Zaheer Udin Babar, Sunil Kumar Dodani, Asma Nasim, Jawahar Lal Langhani, Sanjay Kumar Badlani

The Journal of Infection in Developing Countries · 2023

DOI: 10.3855/jidc.17136 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Infection in Developing Countries, 2023. Verfasst von Zaheer Udin Babar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. Hauptthemen laut MEDLINE: COVID-19, Drug-Related Side Effects and Adverse Reactions, Renal Insufficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Coronavirus disease-19 (COVID-19) is known to cause severe disease in chronic kidney disease and maintenance dialysis patients. We aim to report the outcome of COVID-19 and the adverse effects of Remdesivir (RDV) in patients with renal failure. Methodology: A retrospective observational study included all admitted patients with COVID-19 who received Remdesivir. Clinical characteristics and outcomes were compared in patients with renal failure (RF) and non-renal failure (NRF). We also evaluated RDV-associated nephrotoxicity and observed renal functions during antiviral treatment.

Results

A total of 142 patients received RDV, 38 (26.76%) in RF and 104 (73.23%) in the non-RF group. The median absolute lymphocyte count was low while C-reactive protein, ferritin, and D-dimer were significantly high on admission in the RF group. A significant number of patients in the RF group required ICU admission (58% vs. 35% p = 0.01) and expired (29% vs. 12.5 p = 0.02). Among survivors and non-survivors in the RF group, raised inflammatory markers and low platelet count on presentation were significantly associated with high mortality. Median serum creatinine (mg/dL) was 0.88 on admission, remained at 0.85 in the NRF group, and improved from 4.59 to 3.87 (mg/dL) after receiving five days of RDV in the RF group.

Conclusions

COVID-19 in renal failure has a high risk for ICU admissions leading to increased mortality. Multiple comorbidities and raised inflammatory markers are predictors of poor outcomes. We observed no significant drug-related adverse effects, and none of our patients required discontinuation of RDV due to worsening renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Drug-Related Side Effects and Adverse ReactionsRenal InsufficiencyHumansPakistanCOVID-19 Drug TreatmentAdenosine MonophosphateAlanine

Stichwörter der Autor:innen

COVID-19mortalityremdesivirrenal failure

Substanzen

remdesivirAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
  • Department of Internal Medicine, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.

Zitieren

APA

Babar, Z. U., Dodani, S. K., Nasim, A., Langhani, J. L., & Badlani, S. K. (2023). Outcome of COVID-19 and tolerance of Remdesivir in patients with renal failure: a single center experience from Pakistan. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.17136

Vancouver

Babar ZU, Dodani SK, Nasim A, Langhani JL, Badlani SK. Outcome of COVID-19 and tolerance of Remdesivir in patients with renal failure: a single center experience from Pakistan. The Journal of Infection in Developing Countries. 2023. doi:10.3855/jidc.17136

BibTeX
@article{Babar2023,
  author = {Babar, Zaheer Udin and Dodani, Sunil Kumar and Nasim, Asma and Langhani, Jawahar Lal and Badlani, Sanjay Kumar},
  title = {Outcome of COVID-19 and tolerance of Remdesivir in patients with renal failure: a single center experience from Pakistan},
  journal = {The Journal of Infection in Developing Countries},
  year = {2023},
  doi = {10.3855/jidc.17136}
}
Kostenlos starten →